Matthew Freedman1, Esther H Chang, Qi Zhou, Kathleen F Pirollo. 1. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057-1469, USA.
Abstract
RATIONALE AND OBJECTIVES: Early detection of lung cancer can be problematic. Although current imaging methods can identify lung cancers, they are limited in the size of detectable nodules. There is also lack of evidence that these methods can correctly classify nodules <7 mm as malignant because lung cancer can be mimicked in appearance by benign lesions that lower specificity. Therefore, there is a need for enhanced sensitivity/specificity of detection for small lung cancers. MATERIALS AND METHODS: We have developed a nanosized ( approximately 100 nm) immunoliposome complex for delivery of molecular medicines to tumors. In this complex, an anti-transferrin receptor single-chain antibody fragment (TfRscFv) decorates the surface of a cationic liposome encapsulating the payload. We have previously shown that this systemically administered complex (scL) selectively targets, and efficiently delivers its payload into, tumor cells. We have also encapsulated the magnetic resonance imaging (MRI) contrast agent gadopentetate dimeglumine ("gad-d") within this complex, resulting in increased resolution and image intensity in a mouse model of primary cancer. Here we examine the ability of the scL-gad-d complex to increase the sensitivity of detection of lung metastases. RESULTS: These MRI studies show that the scL-gad-d nanocomplex is able to improve detection, and increase enhancement of, small lung cancers (400 microm and as small as 100 microm) compared to that of uncomplexed gad-d. CONCLUSIONS: Because of its tumor targeting specificity, deliver of an MRI contrast agent via this nanocomplex has potential for use as an agent that can identify small lung cancers, thus improving early detection and possibly increasing survival.
RATIONALE AND OBJECTIVES: Early detection of lung cancer can be problematic. Although current imaging methods can identify lung cancers, they are limited in the size of detectable nodules. There is also lack of evidence that these methods can correctly classify nodules <7 mm as malignant because lung cancer can be mimicked in appearance by benign lesions that lower specificity. Therefore, there is a need for enhanced sensitivity/specificity of detection for small lung cancers. MATERIALS AND METHODS: We have developed a nanosized ( approximately 100 nm) immunoliposome complex for delivery of molecular medicines to tumors. In this complex, an anti-transferrin receptor single-chain antibody fragment (TfRscFv) decorates the surface of a cationic liposome encapsulating the payload. We have previously shown that this systemically administered complex (scL) selectively targets, and efficiently delivers its payload into, tumor cells. We have also encapsulated the magnetic resonance imaging (MRI) contrast agent gadopentetate dimeglumine ("gad-d") within this complex, resulting in increased resolution and image intensity in a mouse model of primary cancer. Here we examine the ability of the scL-gad-d complex to increase the sensitivity of detection of lung metastases. RESULTS: These MRI studies show that the scL-gad-d nanocomplex is able to improve detection, and increase enhancement of, small lung cancers (400 microm and as small as 100 microm) compared to that of uncomplexed gad-d. CONCLUSIONS: Because of its tumor targeting specificity, deliver of an MRI contrast agent via this nanocomplex has potential for use as an agent that can identify small lung cancers, thus improving early detection and possibly increasing survival.
Authors: Stephen J Swensen; James R Jett; Thomas E Hartman; David E Midthun; Jeff A Sloan; Anne-Marie Sykes; Gregory L Aughenbaugh; Medy A Clemens Journal: Radiology Date: 2003-01-24 Impact factor: 11.105
Authors: Kathleen F Pirollo; John Nemunaitis; Po Ki Leung; Robert Nunan; Jana Adams; Esther H Chang Journal: Mol Ther Date: 2016-06-30 Impact factor: 11.454
Authors: Sang-Soo Kim; Antonina Rait; Farwah Rubab; Abhi K Rao; Michael C Kiritsy; Kathleen F Pirollo; Shangzi Wang; Louis M Weiner; Esther H Chang Journal: Mol Ther Date: 2013-10-11 Impact factor: 11.454
Authors: Arlene Siefker-Radtke; Xin-Qiao Zhang; Charles C Guo; Yu Shen; Kathleen F Pirollo; Sharjeel Sabir; Chris Leung; Cindy Leong-Wu; Chi-Ming Ling; Esther H Chang; Randall E Millikan; William F Benedict Journal: Mol Ther Date: 2016-06-13 Impact factor: 11.454
Authors: E R Camp; C Wang; E C Little; P M Watson; K F Pirollo; A Rait; D J Cole; E H Chang; D K Watson Journal: Cancer Gene Ther Date: 2013-03-08 Impact factor: 5.987
Authors: Cristian T Badea; Khannan K Athreya; Gabriela Espinosa; Darin Clark; A Paiman Ghafoori; Yifan Li; David G Kirsch; G Allan Johnson; Ananth Annapragada; Ketan B Ghaghada Journal: PLoS One Date: 2012-04-02 Impact factor: 3.240